MedPath

Effect of Prebiotics on Hyperuricemia

Not Applicable
Conditions
Subjects With Hyperuricemia
Interventions
Dietary Supplement: Placebo control
Dietary Supplement: anserine
Dietary Supplement: Sunflower peptide
Registration Number
NCT05385003
Lead Sponsor
Sun Yat-sen University
Brief Summary

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of Hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of Hyperuricemia through several mechanisms. This trial aims to examine its protective effect in humans.

Detailed Description

Hyperuricemia is a major risk factor for many chronic diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. Animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids.

However, whether administration of prebiotics also has a protective effect in subjects with Hyperuricemia remain unknown.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Local residents aged between 18-65 years old;
  • Stable weight (<5% weight change over last 3 months);
  • Fasting uric acid was > 420μmol/L for male and > 360μmol/L for female on two different days
  • Those who have never taken uric acid lowering drugs or have stopped taking uric acid lowering drugs for at least four weeks;
  • Absence of any diet or medication that might interfere with Uric acid metabolism and gut microbiota, especially antibiotics and probiotics at least 4 weeks before recruitment.
Exclusion Criteria
  • Acute illness or evidence of any acute or chronic inflammatory of infective diseases;
  • Participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment;
  • Mental illness rendering them unable to understand the nature, scope, and possible consequences of the study.
  • Women of childbearing age who are pregnant, breast-feeding or preparing for pregnancy; Patients who had surgery within the past six months or planned surgery during the trial period

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dietary Supplement: Placebo controlPlacebo controlSubjects are instructed to take one capsule of placebo daily for a total of 3 months
Dietary Supplement: anserineanserineSubjects are instructed to take one capsule of anserine daily for a total of 3 months
Dietary Supplement: Sunflower peptideSunflower peptideSubjects are instructed to take one capsule of Sunflower peptide daily for a total of 3 months
Primary Outcome Measures
NameTimeMethod
Change of excretion of uric acidfrom baseline to 12 weeks after intervention

excretion rate of uric acid assessed by secretion rate of uric acid in urine during 3 hours

Change of serum Uric acidfrom baseline to 12 weeks after intervention

change of fasting uric acid level assessed by biochemical detector

Secondary Outcome Measures
NameTimeMethod
Change of Microbial metabolitesfrom baseline to 12 weeks after intervention

Untargeted metabolomics will be used to assess the alterations of microbial metabolites with High performance liquid chromatography-mass spectrometry

Change of Gut microbiotafrom baseline to 12 weeks after intervention

Alterations of the composition of gut microbiota evaluated by metagenomics

Change in lipid profilesfrom baseline to 12 weeks after intervention

Change in total cholesterol, triglycerides, LDL-c and HDL-c assessed by biochemical detector

Change in blood pressurefrom baseline to 12 weeks after intervention

Change in blood pressure assessed by electronic sphygmomanometer

Change in fasting glucosefrom baseline to 12 weeks after intervention

Change in fasting glucose assessed by biochemical detector

Change in waist circumferencefrom baseline to 12 weeks after intervention

Change in waist circumference assessed by tape

Trial Locations

Locations (2)

Sun Yat-Sen University

🇨🇳

Guangzhou, Guangdong, China

Department of Nutrition and Food Hygiene

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath